Penumbra, Inc.

Equities

PEN

US70975L1070

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 16:00:02 2024-05-17 EDT			5-day change	1st Jan Change
203.5 ^USD	+0.99%		-4.12%	-19.09%

05-15	Transcript : Penumbra, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-15-2024 08:00 AM
05-08	Morgan Stanley Cuts Price Target on Penumbra to $235 From $240, Keeps Equalweight Rating	MT

Penumbra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 07, 2024 at 04:05 pm

Penumbra, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 278.66 million compared to USD 241.4 million a year ago. Net income was USD 11 million compared to USD 8.56 million a year ago.

Basic earnings per share from continuing operations was USD 0.28 compared to USD 0.22 a year ago. Diluted earnings per share from continuing operations was USD 0.28 compared to USD 0.22 a year ago.

Latest news about Penumbra, Inc.

Transcript : Penumbra, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-15-2024 08:00 AM	05-15
Morgan Stanley Cuts Price Target on Penumbra to $235 From $240, Keeps Equalweight Rating	05-08	MT
Penumbra Q1 Non-GAAP EPS, Revenue Increase; Reaffirms 2024 Revenue Outlook	05-07	MT
Transcript : Penumbra, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Earnings Flash (PEN) PENUMBRA Reports Q1 Revenue $278.7M, vs. Street Est of $274.5M	05-07	MT
Earnings Flash (PEN) PENUMBRA Reports Q1 EPS $0.41, vs. Street Est of $0.38	05-07	MT
Penumbra, Inc. Reiterates Earnings Guidance for the Year 2024	05-07	CI
Penumbra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Penumbra, Inc. Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots	04-23	CI
DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	04-17	MT
Penumbra, Inc. : The underdog in healthcare	04-11
Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate	03-27	MT
Truist Securities Cuts Penumbra's Price Target to $280 From $290, Keeps Buy Rating	03-22	MT
Piper Sandler Adjusts Price Target on Penumbra to $290 From $310, Maintains Overweight Rating	02-26	MT
North American Morning Briefing : Traders Await -2-	02-26	DJ
Deutsche Bank Raises Penumbra Price Target to $288 From $257, Maintains Buy Rating	02-23	MT
Truist Securities Cuts Price Target on Penumbra to $290 From $300, Maintains Buy Rating	02-23	MT
Traders Await Fresh Cues After Nvidia-Fueled Rally as US Equity Futures Inch Higher Pre-Bell	02-23	MT
JPMorgan Downgrades Penumbra to Neutral From Overweight, Cuts Price Target to $250 From $284	02-23	MT
Penumbra Q4 Non-GAAP EPS, Revenue Increase; Shares Fall After-Hours	02-22	MT
Transcript : Penumbra, Inc., Q4 2023 Earnings Call, Feb 22, 2024	02-22
Earnings Flash (PEN) PENUMBRA Posts Q4 Revenue $284.7M, vs. Street Est of $286.5M	02-22	MT
Earnings Flash (PEN) PENUMBRA Reports Q4 EPS $0.76, vs. Street Est of $0.70	02-22	MT
Penumbra, Inc. Provides Earnings Guidance for the Full Year 2024	02-22	CI
Penumbra, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-22	CI

Chart Penumbra, Inc.

Duration

Period

More charts

Company Profile

Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-06-04 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Penumbra, Inc. : The underdog in healthcare

April 11, 2024 at 09:39 pm

More Strategies

Ratings for Penumbra, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

203.5 USD

Average target price

269.2 USD

Spread / Average Target

+32.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
PENUMBRA, INC.	-19.09%	7.89B
SHOCKWAVE MEDICAL, INC.	+73.24%	12.39B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+13.24%	5.43B
APT MEDICAL INC.	+38.48%	4.96B
GETINGE AB	-17.30%	4.72B
ASAHI INTECC CO., LTD.	-19.78%	4.02B
INARI MEDICAL, INC.	-29.53%	2.66B
NOVOCURE LIMITED	+47.29%	2.37B
SKAN GROUP AG	-2.10%	1.96B
SHENZHEN YHLO BIOTECH CO., LTD.	+6.56%	1.92B

Medical Equipment